Convenia

Convenia is a veterinary pharmaceutical product that contains cefovecin sodium, a long-acting cephalosporin antibiotic. It is marketed for use in dogs and cats and is typically administered as a single subcutaneous injection, providing therapeutic concentrations for an extended period and reducing the need for daily medications.

Pharmacology and use: Cefovecin is a third-generation cephalosporin with an extended half-life that allows sustained plasma levels after a subcutaneous dose. It achieves good distribution to skin and soft tissues, supporting its use in treating infections in these areas. The product is primarily indicated for skin and soft tissue infections in dogs and cats, with potential use in other soft tissue infections as determined by a veterinarian.

Indications and spectrum: Convenia is indicated for uncomplicated pyoderma and other skin infections in companion animals. It has broad activity against many organisms commonly implicated in canine and feline skin conditions, including several Gram-positive cocci and some Gram-negative bacteria. The exact spectrum can vary with local susceptibility patterns.

Administration and dosing: The medication is given by subcutaneous injection. In many cases, a single dose suffices, with the possibility of a second dose after about two weeks if clinical response is not adequate, under veterinary guidance.

Safety and regulation: Reported adverse effects are generally mild and may include injection-site swelling, vomiting, or diarrhea. Serious allergic reactions are rare. It should be avoided in animals with known hypersensitivity to cephalosporins or penicillins. Convenia is approved for veterinary use in dogs and cats in many countries and is distributed by Zoetis.